-
1.发明公开公开(公告)号：US20240228464A9
公开(公告)日：2024-07-11
申请号：US18383949
申请日：2023-10-26
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Guoqiang Wang , Ruichao Shen , Brett Granger , Jing He , Xuechao Xing , Yong He , Jiang Long , Jun Ma , Bin Wang , Yat Sun Or
IPC: C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14
CPC classification number: C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof:
which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which is associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).-
公开(公告)号：US20240207224A1
公开(公告)日：2024-06-27
申请号：US18509403
申请日：2023-11-15
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Jiajun Zhang , Xuri Gao , Hui Cao , Yuk Ming Siu , Bin Wang , Jiang Long , Wei Li , Matthew C. Rhodes , Xuechao Xing , Scott Mitchell , Yat Sun Or
IPC: A61K31/395 , A61K31/4192 , A61K31/4995 , A61P31/14 , C07D225/04 , C07D245/04 , C07D255/04 , C07D273/02 , C07D281/00 , C07D285/00 , C07D487/08
CPC classification number: A61K31/395 , A61K31/4192 , A61K31/4995 , A61P31/14 , C07D225/04 , C07D245/04 , C07D255/04 , C07D273/02 , C07D281/00 , C07D285/00 , C07D487/08
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof:
which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.-
公开(公告)号：US11976084B2
公开(公告)日：2024-05-07
申请号：US17531844
申请日：2021-11-22
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Guoqiang Wang , Ruichao Shen , Jun Ma , Yong He , Xuechao Xing , Hui Cao , Xuri Gao , Xiaowen Peng , Joseph D. Panarese , Yat Sun Or
IPC: C07D519/00
CPC classification number: C07D519/00
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof:
which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.-
公开(公告)号：US20220162216A1
公开(公告)日：2022-05-26
申请号：US17479244
申请日：2021-09-20
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Guoqiang Wang , Ruichao Shen , Yong He , Xuri Gao , Jun Ma , Xuechao Xing , Hui Cao , Joseph D. Panarese , Yat Sun Or
IPC: C07D487/10
Abstract: The present invention discloses compounds of Formula (Ia), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US11034684B2
公开(公告)日：2021-06-15
申请号：US16569819
申请日：2019-09-13
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Jun Ma , Guoqiang Wang , Bin Wang , Xuechao Xing , Ruichao Shen , Jing He , Yat Sun Or
IPC: C07D417/14 , C07D413/14 , C07D261/08 , C07D413/12
Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.
-
Patent Agency Ranking
6.发明授权公开(公告)号：US11008304B2
公开(公告)日：2021-05-18
申请号：US16400529
申请日：2019-05-01
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Guoqiang Wang , Ruichao Shen , Brett Granger , Jing He , Xuechao Xing , Yong He , Jiang Long , Jun Ma , Bin Wang , Yat Sun Or
IPC: C07D401/14 , C07D413/14 , C07D405/14 , C07D409/14 , C07D417/14
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which is associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
-
公开(公告)号：US10676500B2
公开(公告)日：2020-06-09
申请号：US15948370
申请日：2018-04-09
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Guoqiang Wang , Yong He , Brett Granger , Xuechao Xing , Yat Sun Or
Abstract: The present invention relates to processes for preparing compounds of Formula (I) and compounds of Formula (II): These compounds are useful as FXR or TGR5 modulators. The present invention also relates to processes for the preparation of the compounds of Formula (III), Formula (IV), Formula (V), and Formula (VI), The present invention also relates to a process for the preparation of compounds (VII), (VIII) and (IX),
-
公开(公告)号：US20200157095A1
公开(公告)日：2020-05-21
申请号：US16688429
申请日：2019-11-19
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Brett Granger , Guoqiang Wang , Ruichao Shen , Jing He , Yong He , Xuechao Xing , Jun Ma , Jiang Long , Bin Wang , Yat Sun Or
IPC: C07D471/04 , C07D401/14 , C07D413/14 , C07D405/14 , C07D417/14
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
-
公开(公告)号：US20200079764A1
公开(公告)日：2020-03-12
申请号：US16569819
申请日：2019-09-13
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Jun Ma , Guoqiang Wang , Bin Wang , Xuechao Xing , Ruichao Shen , Jing He , Yat Sun Or
IPC: C07D413/14 , C07D413/12 , C07D261/08 , C07D417/14
Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.
-
公开(公告)号：US20190248777A1
公开(公告)日：2019-08-15
申请号：US16272506
申请日：2019-02-11
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Ruichao Shen , Jun Ma , Guoqiang Wang , Xuechao Xing , Yat Sun Or
Abstract: The present invention provides compounds of Formula (I): pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.
-
-
-
-
-
-
-
-
-
Search Results
93
records
(took 0.03 seconds)
